In patients with microsatellite stable (MSS) disease, comutations in RNF43 were associated with improved efficacy outcomes after BRAF-targeted therapy compared with patients with wt RNF43 tumors.17 In our study, 13 patients had MSS colon cancer. The gene discussed is RNF43; the disease is malignant colon neoplasm.